Scailyte raises €6.3M Series A round
19 September 2022· Basel, Switzerland· health, precision_medicine, ai, biotech, pure_software, b2b
advancing the endometriosis biomarker into the prototype validation stage in the United States as the primary target market, building strategic partnerships in single-cell omics, cell & gene therapy, and translational oncology to increase the success rate of novel cancer therapies in the clinic, expanding the discovery capabilities of ScaiVision
Investors
LeadSwiss family office
Also participating
Swisscom Venturesprevious investorsMirabaud bank
About Scailyte
Stage
Series A
Headquarters
Basel, Switzerland
Founded
2017
Team Size
21–50
Sectors
healthprecision_medicineaibiotechpure_softwareb2b